Диссертация (1154834), страница 27
Текст из файла (страница 27)
/ P.B. Ernst // Basic mechanismst clinical cure. – 2000. –Vol.14 – P. 141 -150.161247. Fock, K. M. Functional dyspepsia, Helicobacter pylori and postinfectious functional dyspepsia / K.M. Fock // Journal of Gastroenterology andHepatology. – 2011. – Vol. 26 (3). – Р. 39-41.248. Fuller, R. Gut Flora, Nutrition, Immunity and Health / R.Fuller, G,Perdigon // Blackwell Publishing. – 2003. – 275 P.249.Georgopoulos, S.D.
Helicobacter pylori eradication therapies in theera of increasing antibiotic resistance: A paradigm shift to improved efficacy / S.D.Georgopoulos, V. Papastergiou, S. Karatapanis // Gastroenterol. Res. Pract. –2012. – Vol. 12. – P. 757–926.250. Gooz, M. Inhibition of human gastric H+-K+-ATPase-subunit geneexpression by Helicobacter pylori / M. Gooz, C.E. Hammond , K. Larsen [ et al.
]// AJP – GI. – 2000. – Vol. 278 (6). – P.981-989.251.Graham, D.Y. Helicobacter pylori treatment in the era of increasingantibiotic resistance / D.Y. Graham, L. Fischbach // Gut. – 2010. – Vol. 59 (8). – P.1143-1153.252. Hudson, N. Successful H. pylori eradication incorporating a one-weekantibiotic regimen / N.
Hudson, W.G. Brydon , M.A. Eastwood // Aliment.Pharmacol. Ther. – 1995. – Vol. 9. – P. 47-50.253. Indrio, F.Влияние пробиотиков на опорожнение желудка умладенцев / F. Indrio, G. Riezzo, F. Raimondi, M. Bisceglia, L. Cavallo //Verman. – 2012 .– Р.
11-14.254. Jiang, T. Gas production by feces of infants / T. Jiang, F. Suarez, M.Levitt// J. Pediatr. Gastroenterol. Nutr. – 2001. – Vol. 32 (5). – P. 534-541.255. Kandelaki, S. Helicobacter and hepatobiliary diseases: conceptualview and review of the literature / S.
Kandelaki, D. Kordzaia // Georgian Med.News. – 2014. – Vol. 232. – P. 92-98.256.Krzyżek, P. Rola Helicobacter pylori w regulowaniu aktywnościhormonów przewodu pokarmowego / Paweł Krzyżek // Endokrynol. Ped. – 2017. –Vol.16. – Р. 235-242.162257. Lauren, H. An updated systematic review and meta-analysis on theassociation between Helicobacter pylori infection and iron deficiency anemia/L.Hudak, A. Jaraisy, S. Haj // Helicobacter. – 2017.
– Vol. 1 (22). – Р. 16.258. Leal-Lopes, C. Roles of Commensal Microbiota in PancreasHomeostasis and Pancreatic Pathologies/ C. Leal-Lopes, F.J. Velloso, J.C.Campopiano // J. Diabet Res. – 2016. – Vol. 21 (3 ). – P. 1-19.259. Lee, Y.C.
Association Between Helicobacter pylori Eradication andGastric Cancer Incidence: a Systematic Review and Meta-analysis / Y.C. Lee, T.H.Chiang, C.K. Chou [ et al. ] // Gastroenterology. – 2016. –Vol. 150 (5). P. 11131124.260.Leidy, N.K. Recommendations for evaluating the validity of qualityof life claims for labeling and promotion / N.K. Leidy, D.A. Revicki, B. Geneste //Value Health. – 1999. – Vol. 2.
– P. 113-27.261. Levi L. Guidance on Work Related Stress. Luxembourg / L. Levi, I.Levi: European Comission. – 2000. – P.154-156.262. Li, B.Z. Comparative effectiveness and tolerance of treatments forHelicobacter pylori: systematic review and network metaanalysis / B.Z. Li, D.E.Threapleton, J.Y.
Wang [ et al. ] // BMJ. – 2015. – Vol. 19. – P. 351.263. Luckey, A. Mechanisms and treatment of postoperative ileus / A.Luckey, E. Livingston, Y. Taché // Arch Surg. – 2003. – Vol. 138 (2). – P. 206214.264. Malfertheiner, P. Guidelines for the Management of Helicobacterpylori Infection Summary of the Maastricht-3 2005 Consensus Report / P.Malfertheiner, F. Megraud, C. O’Morain // Вusiness briefing: Еuropeangastroenterology review.
– 2005. – Vol. 56 – Р. 59-60.265. Malfertheiner, P. Current concepts in the management of Helicobacterpylori infection: the Maastricht III consensus report / P. Malfertheiner [ et al. ] //Gut. – 2007. – Vol. 56. – Р. 772-781.266. Malfertheiner, P. European Helicobacter Study Group. Managementof Helicobacter pylori infection the Maastricht IV. / P. Malfertheiner, F. Megraud,163C. O’Morain // Florence Consensus Report Gut.
– 2012. – Vol. 61 (7). – P. 646664.267. Malfertheiner, P. Management of Helicobacter pylori infection – theMaastricht V/ P. Malfertheiner, F.Megraud, C.A. O’Morain [ et al. ] // FlorenceConsensus Report. – 2017. – Vol. 66. – P. 6-30.268. Maslowski, K.M. Diet, gut microbiota and immune responses / K.M.Maslowski, C.R. Mackay// Nat. Immunol. – 2011.
– Vol. 12. – P. 5-9.269. Medeiros, J.A. Evaluation of Helicobacter pylori eradication by tripletherapy plus Lactobacillus acidophilus compared to triple therapy alone /J.A.Medeiros, T.M. Gonçalves [ et al. ] // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. –Vol. 30.– P. 555-559.270. Mеgraud, F. Surveillance of Helicobacter pylori resistance toantibiotics in France in 2014 / F. Mеgraud, A. Ducournau, E. Bеnеjat [ et al. ]Helicobacter.
– 2016. – Vol. 21. P.110-114.271. Mentis, А. Epidemiology and Diagnosis of Helicobacter pyloriinfection / A. Mentis, P.Lehours, F.Mégraud // Helicobacter. – 2016. – Vol. 20 (1).P. 1-7.272.Michael, P. Mood and Anxiety Disorders Precede Development ofFunctional Gastrointestinal Disorders in Patients but Not in the Population / P.Michael, J.Tack, L.V.
Oudenhove e.a. // Clinical Gastrenterology and Hepatology– 2017. – Vol. 7 (15). – P. 1014-1020.273. Miossec, P. Interleukin-17 and type 17 helper T-cells / P. Miossec, T.Korn, V. Kuchroo // N. Engl.J. Med. – 2009. – Vol. 361. – P.888-898.274. Moayyedi, P. Eradication of Helicobacter pylori for non-ulcerdyspepsia / P. Moayyedi, S. Soo, J. Deeks [ et al. ] // Cochrane Database Syst. Rev.– 2006.– Vol. 25 (1). – P.110-116.275. Morais, S. Contemporary migration patterns in the prevalence ofHelicobacter pylori infection: A systematic review / S. Morais, A.
Rute Costa, A.Ferro [ et al. ] // Helicobacter. – 2017. – № 3. – P. 1-11.164276. Nimish, B. White Paper AGA: Functional Dyspepsia/ B. Nimish, W.Colin, P. Moayyedi, J. Tack // Clinical Gastrenterology and Hepatology – 2017. –Vol. 8 (15). – P. 1191-1194.277. Norgaard, A. Specific neutrophil hyporesponsiveness in chronicHelicobacter pylori infection / A. Norgaard, L.P. Andersen, L. Elsborg [et al.] // JInfect Dis. – 1996. – Vol.174(3). – P.544-551.278. Ohata, H. Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer / H. Ohata, S.Kitauchi, N. Yoshimura [ et al.
] // Int. J. Cancer. – 2004. – Vol.109 (1). – P. 138143.279. Okuda, М. Diagnostic accuracy of urine Helicobacter pylori antibodytest in junior and senior high school students in Japan / M. Okuda, K. Mabe, S.Rikuch / /Helicobacter. – 2016. – Vol. 21.– P. 78.280. Peeters, T.L. Central and peripheral mechanisms by with ghrelinregulates gut motility / T.L.
Peeters // J. Physiol. Pharmacol. – 2003. – Vol. 54 (4).– P. 95-103.281. Peura, D.A. Treatment of Helicobacter pylori infection / D.A. Peura //Therapy of digestive disorders / Ed. M.M. Wolfe. – Philadelphia: Elsevier. – 2006.– Vol. 26. – P. 277.282. Peura, D.A. Helicobacter pylori / D.A. Peura, S. E. Crowe //Sleisenger & Fordtran’s gastrointestinal and liver disease / Eds. M. Feldman, L.S.Friedman, L.J. Brandt. – 9th ed. – Philadelphia, Pa: Saunders Elsevier. – 2010. – 50P.283. Price, A.B. The Sydney system: histological division / A.B. Price // JGastroenterol Hepatol. – 1991. – Vol.
6. – P.209-222.284. Reid, G. Probiotics: definition, scope and mechanisms of action / G.Reid // Best Pract Res Clin Gastroenterol. – 2016. – Vol. 30 (1). – P. 17-25.285. Reshetnicov, O.V. Seroprevalence of Helicobacter pylori infection inSiberia / O.V. Reshetnicov, V.M. Haiva, C. Granberg // Helicobacter. – 2001. –Vol. 6. – P.331-336.165286. Ruggiero, P.
Helicobacter pylori infection: what is new / P. Ruggiero// Curr. Opin. Infect. Dis. – 2012. – Vol. 25 (3). – P. 337-344.287. Ryan, J. L. Epstein-Barr virus infection is common in inflamedgastrointestinal mucosa / J. L. Ryan, Y. J. Shen, D. R. Morgan [ et al. ] // Dig. Dis.Sci. – 2012. – Vol.
57. – Р. 1887-1898.288. Scaccianoce, G. Helicobacter pylori eradication with either 7-day or10-day triple therapies, and with a 10 – day sequential regimen / G. Scaccianoce,C.Hassan [ et al. ] // Can. J. Gastroenterology. – 2006. – Vol. 20 (2).– P. 113-117.289. Scotiniotis, I.A. Altered gastric epithelial cell kinetics in Helicobacterpylori-associated intestinal metaplasia: implications for gastric carcinogenesis /I.A. Scotiniotis // Int. J. Cancer. – 2000.
– Vol. 85 (2). – P. 192-200.290. Selby, W.S. Lymphocytes subpopulation in the human small intestine.The finding in normal mucosa / W.S. Selby // Clin. Exp. Immunol. – 2003. – Vol.52. – P. 219-228.291. Stenstrom, B. Helicobacter pylori – The latest in diagnosis andtreatment / B.
Stenstrom, A. Mendis, B. Marshall // Aust.Fam.Physician. – 2008.–Vol. 37.– P. 608-612.292. Sykora, J. Effects of a specially designed fermented milk productcontaining probiotic Lactobacillus casei DN-114 001 and the eradication of H.pylori in children: a prospective randomized double-blind study/ J. Sykora, K.Valeckova, J.Amlerova [ et al. ] // J. Clin. Gastroenterol. – 2005. –Vol.39. – P.692-698.293. Tack, J. Functional Gastroduodenal Disorders / J.Tack, N.J.Talley, M.Camilleri [ et al. ] // Am. J.
Gastroenterology. – 2006. – Vol. 130 (5). – P.14661479.294. Tack, J. Efficacy of Buspirone, a fundus-Relaxing drug, in patientswith functional dyspepsia /J. Tack, P. Janssen, T. Masaoka // ClinicalGastrenterology and Hepatology. – 2012. – Vol. 11 (10). – P. 1239-1245.166295.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
